The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients.
 
Olumide B. Gbolahan
No Relationships to Disclose
 
Neda Hashemi-Sadraei
No Relationships to Disclose
 
Abass Conteh
No Relationships to Disclose
 
Hristos Z. Kaimakliotis
No Relationships to Disclose
 
Walter Storkus
No Relationships to Disclose
 
Roberto Pili
Consulting or Advisory Role - Exelixis; Ipsen; Prometheus
Research Funding - Active Biotech; ARIAD; Millennium; Peregrine Pharmaceuticals; Pfizer; Syndax
 
Theodore F. Logan
Consulting or Advisory Role - Prometheus
Research Funding - Abbott Laboratories (Inst); Abraxis BioScience (Inst); Acceleron Pharma (Inst); Amgen (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BioVex (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Dynavax Technologies (Inst); Eisai (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche (Inst); Synta (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)